Update on treatment of polymyalgia rheumatica

Abstract

Polymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic disease in the elderly after rheumatoid arthritis. It is clinically characterised by pain and stiffness in the neck, proximal shoulder and hip girdle. Glucocorticoids (GCs) are the cornerstone of PMR treatment, but they are associated with potentially severe side effects. Among GC-sparing agents, methotrexate revealed a modest benefit in clinical trials, and recently, there have been promising reports from tocilizumab. In this review, we summarize the available evidence on the treatment of PMR and the possible role in the future of other agents under investigation.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Author Biography

D. Camellino, Division of Rheumatology, Locomotor Apparatus Department, La Colletta Hospital, ASL3 Genovese, Arenzano (GE); Autoimmunology Lab, Department of Internal Medicine, University of Genova
Specializzando in Reumatologia
Published
2018-03-27
Keywords:
Polymyalgia rheumatica, large vessel vasculitis, glucocorticoids, disease modifying anti-rheumatic drugs, biologics.
Statistics
  • Abstract views: 3967

  • PDF: 2386
How to Cite
Camellino, D., & Dejaco, C. (2018). Update on treatment of polymyalgia rheumatica. Reumatismo, 70(1), 59-66. https://doi.org/10.4081/reumatismo.2018.1062